Storia in 3 fonti

Braveheart Bio jumps 68% in trading debut after $383M IPO

Braveheart Bio shares surged 68% in their Nasdaq debut after a $382.5M IPO, pushing the cardiovascular biotech's market cap past $2 billion.

Raccontata da

biopharmadive.com

endpoints.news

cryptobriefing.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

cryptobriefing.comStai leggendo16 h fa

Braveheart Bio jumps 68% in trading debut after $383M IPO

Braveheart Bio raised $382.5M at $18 IPO; stock jumped 68% to $30, valuing the pre-revenue cardiac biotech at $2.1B. Pop signals biotech IPO window reopened; investors betting on Phase-3 catalyst, though the 68% gap cost shareholders hundreds of millions.

originale

biopharmadive.com3 g fa

Cardiac drug developer Braveheart banks more than $382M in IPO

Braveheart Bio priced IPO at $18 per share, raising $382.5M; Nasdaq debut Thursday (ticker BRVE). The cardiac biotech, founded 2024, develops BHB-1893—a myosin inhibitor licensed from Hengrui Pharma—competing against Camzyos; it's the 17th drugmaker IPO in 2026.

Leggi questa versione →

Timeline cronologica

mercoledì 5 agosto 2026·biopharmadive.com
Cardiac drug developer Braveheart banks more than $382M in IPO
Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ultimately be more than $1 billion from public investors.
giovedì 6 agosto 2026·endpoints.news
Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3
Braveheart Bio prices $382.5M IPO, tapping Hengrui-licensed BHB-1893 to challenge Bristol Myers' Camzyos and Cytokinetics' Myqorzo in cardiomyopathy.

Braveheart Bio jumps 68% in trading debut after $383M IPO

Cardiac drug developer Braveheart banks more than $382M in IPO

Timeline cronologica

Cardiac drug developer Braveheart banks more than $382M in IPO

Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3

Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3

Braveheart Bio jumps 68% in trading debut after $383M IPO